Sapacitabine
Phase 3Small molecule
Sapacitabine is one of 230 small molecule programs targeting Cutaneous T-cell lymphoma. It is currently in Phase 3.
6
Indications
8
Total Trials
1
Active Trials
229
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Sapacitabine
CCyclacel Pharmaceuticals, Inc.
Phase 3
Tecentriq
RochePreclinical
Trodelvy
GileadPreclinical
Halaven
EisaiPreclinical
Tykerb
GSKPreclinical
Nolvadex
SSan Diego Pacific Oncology & Hematology Associates
Preclinical
Adriamycin
GGynecologic Oncology Group
Preclinical
Avastin
BBio-Thera Solutions
Preclinical
Prolia
AmgenPreclinical
Gemzar
GGynecologic Oncology Group
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Myelodysplastic Syndromes2 trials
Acute Myeloid Leukemia1 trial
Chronic Lymphocytic Leukemia1 trial
Patients With Advanced Solid Tumors1 trial
2 more indications
Breast Cancer1 trial
Olaparib + Sapacitabine in BRCA Mutant Breast Cancer
Active, not recruiting·—·Phase 1·NCT03641755·10 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sapacitabine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- CCyclacel Pharmaceuticals, Inc.